Millendo Therapeutics Operating Income

The latest operating income for MLND is $-17M as of March 2026. That compares with $-330K in the prior-year period — down 4955.1% year over year. Investors often review this figure alongside Millendo Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MLND's operating income moved from $-330K to $-17M — a 4955.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Millendo Therapeutics's operating scale or balance-sheet position.

A operating income figure of $-17M for MLND is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MLND's operating income ($-17M), review year-over-year change from $-330K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Millendo Therapeutics's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.